Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESIT-CSU: IL-2 for Refractory Chronic Spontaneous Urticaria
NCT06924762Phase 3Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic spontaneous urticaria (CSU) comparing Interleukin-2 Group with Placebo Group (2 arms). Primary endpoint: Change from Baseline in the Urticaria Activity Score of 7 Days (UAS7) at 12 weeks. Started Mar 2025; status: recruiting.
02
Drugs
aldesleukin
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06924762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06924762.